Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Baxter International Inc. (BAX): A Bull Case Theory

2025-12-18
We came across a bullish thesis on Baxter International Inc. on Value investing subreddit by Mr-Gambini. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.’s share was trading at $19.29 as of December 17th. BAX’s forward P/E was 8.12 according to Yahoo Finance. Baxter International (BAX) is a quintessential “boring but essential” medtech company operating in oligopolistic markets for […]

BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care

2025-12-15
Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.

Baxter International Stock: Is BAX Underperforming the Health Care Sector?

2025-12-12
Baxter International has lagged the broader health care sector by a wide margin over the past year, and analysts are taking a guarded stance on its outlook.

Is Baxter International Offering Long Term Value After Years of Share Price Declines?

2025-12-12
Wondering if Baxter International is a beaten down healthcare name or a genuine value opportunity at today’s price? Let’s unpack what the market might be missing. The stock has inched up 2.3% over the last week and 3.6% over the past month, but that is against a much steeper backdrop with returns of -35.4% year to date and a -74.0% slide over five years. Investors have been reacting to Baxter’s ongoing portfolio reshaping, including moves to streamline its medical products business and...

How Tender Offers And A Class I Recall At Baxter International (BAX) Have Changed Its Investment Story

2025-12-11
In early December 2025, Baxter International launched cash tender offers to buy back any and all of its 2.600% senior unsecured notes due 2026, and up to US$600 million of its 1.915% senior unsecured notes due 2027, as detailed in an amended offer to purchase document. At the same time, Baxter has been hit with multiple class action lawsuits and an FDA Class I recall over safety defects in its Novum IQ Large Volume Pump, raising fresh questions about product quality oversight and legal risk...

Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

2025-12-11
DEERFIELD, Ill., December 11, 2025--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medical Branch (UTMB Health) demonstrating the positive impact of smart infusion pump integration with hospital electronic medical records (EMRs) on patient safety, clinicians' bedside productivity and programming compliance. The analyses of more than one million infusions on Baxter’s Spectrum IQ

Q3 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks

2025-12-11
Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Baxter (NYSE:BAX) and its peers.

Here’s What Pressured Baxter International (BAX) in Q3

2025-12-10
Pzena Investment Management recently released its third-quarter 2025 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. Driven by optimism about AI and a September rate cut, US broad-based indexes surged in the third quarter. The technology sector was the strongest performer, with growth outpacing value. The Pzena Focused […]

Scrooge: 5 Stocks That Could Ruin Your Santa Rally

2025-12-10
Investors are betting on a Santa rally, but weak stocks could eat your gains. Don’t let greed steal your profits. Here are 5 stocks to sell now.

Wall Street Analysts Have Consensus Hold Recommendation For Baxter International Inc. (BAX)

2025-12-09
Baxter International Inc. (NYSE:BAX) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On December 2, Morgan Stanley analyst Patrick Wood cut his price target on the stock to $15 from $19 while keeping an Underweight rating. Looking ahead to 2026, the analyst told investors in a research note that […]